Biotech entity
All 1 tracked stories fall under one category: fda-approval. ORIGIN 3 is most often covered alongside Marshall Fordyce, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention ORIGIN 3, all published on July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. ORIGIN 3 is most often covered alongside Marshall Fordyce, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention ORIGIN 3, all published on July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ORIGIN 3. Shared-story counts are live from our verified record — not editorial picks.
Vera Therapeutics scores an accelerated approval for TRUTAKNA in IgA nephropathy, touting a 42% UPCR reduction vs placebo in Phase 3 ORIGIN 3. The dual BAFF/APRIL inhibitor enters a competitive market with a surrogate endpoint—investors await the confirmatory eGFR data.
Source: dailypolitical.com · tickerreport.com
ORIGIN 3 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
